Tamoxifen (correction)

01 Oct 2007
News

Executive Summary

Tamoxifen is a selective estrogen receptor modulator. An article about new indications for Lilly's osteoporosis drug Evista described tamoxifen as an aromatase inhibitor. Additionally, Lilly's arzoxifene is in Phase III studies for prevention of invasive breast cancer and treatment of osteoporosis - Phase III studies for the treatment of metastatic breast cancer are not underway (1"The Pink Sheet" Sept. 24, 2007, p. 16)...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS048849

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS048849

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Tamoxifen (correction)

News

Executive Summary

Related Content

Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning

Evista Gains Breast Cancer Risk Reduction Claim But Adds Black Box Warning

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert